Juan Andres Asturias
Research Subjects
Juan Andres Asturias has a total of 437 co-authors. Here are the top co-authors by number of shared publications:
A. Martínez
20 shared publicationsAlberto Martínez
ROXALL España, R&D Department, Zamudio, Spain
15 shared publicationsI. Ibarrola
15 shared publicationsIgnacio Ibarrola
Research and Development Department, BIAL-Arístegui, Bilbao, Spain
8 shared publications- Jorge Martínez
Department of Immunology, Microbiology and Parasitology, Faculty of Pharmacy, University of the Basque Country, Vitoria, Spain
8 shared publications M. C. Arilla
Bial‐Arístegui, Research & Development Department, Bilbao, Spain
8 shared publications
Latest Publications
- 25 June 2019
- Published by Taylor & Francis in Immunotherapy
- Vol. 11 (12) , 1031-1042
Tolerability and surrogate efficacy parameters of a polymerized depot mixture pollen extracts without dilutional effect
Aim: To evaluate tolerability of subcutaneous immunotherapy, in a polymerized mixture (Olea europaea/Phleum pratense) depot presentation. Patients & methods: A total of 47 poly-allergic patients re...
- 25 June 2019
- Published by Taylor & Francis in Immunotherapy
- Vol. 11 (12) , 1031-1042
Tolerability and surrogate efficacy parameters of a polymerized depot mixture pollen extracts without dilutional effect
Aim: To evaluate tolerability of subcutaneous immunotherapy, in a polymerized mixture (Olea europaea/Phleum pratense) depot presentation. Patients & methods: A total of 47 poly-allergic patients re...
- Open Access
- 17 June 2019
- Published by Wiley in Molecular Nutrition & Food Research
- Vol. 63 (18) , e1900336
Rational Design, Structure–Activity Relationship, and Immunogenicity of Hypoallergenic Pru p 3 Variants
Scope: Allergies to lipid transfer proteins involve severe adverse reactions; thus, effective and sustainable therapies are desired. Previous attempts disrupting disulfide bonds failed to maintain immunogenicity; thus, the aim is to design novel hypoallergenic Pru p 3 variants and evaluate the applicability for treatment of peach allergy.Methods and results: Pru p 3 proline variant (PV) designed using in silico mutagenesis, cysteine variant (CV), and wild‐type Pru p 3 (WT) are purified from Escherichia coli. Variants display homogenous and stable protein conformations with an altered secondary structure in circular dichroism. PV shows enhanced long‐term storage capacities compared to CV similar to the highly stable WT. Using sera of 33 peach allergic patients, IgE‐binding activity is reduced by 97% (PV) and 71% (CV) compared to WT. Both molecules show strong hypoallergenicity in Pru p 3 ImmunoCAP cross‐inhibition and histamine release assays. Immunogenicity of PV is demonstrated with a phosphate‐based adjuvant formulation in a mouse model.Conclusions: An in silico approach is used to generate a PV without targeting disulfide bonds, T cell epitopes, or previously reported IgE epitopes of Pru p 3. PV is strongly hypoallergenic while structurally stable and immunogenic, thus representing a promising candidate for peach allergen immunotherapy.
- 17 June 2019
- Published by Wiley in Molecular Nutrition & Food Research
- Vol. 63 (18) , e1900336
Open AccessRational Design, Structure–Activity Relationship, and Immunogenicity of Hypoallergenic Pru p 3 Variants
Scope: Allergies to lipid transfer proteins involve severe adverse reactions; thus, effective and sustainable therapies are desired. Previous attempts disrupting disulfide bonds failed to maintain immunogenicity; thus, the aim is to design novel hypoallergenic Pru p 3 variants and evaluate the applicability for treatment of peach allergy.Methods and results: Pru p 3 proline variant (PV) designed using in silico mutagenesis, cysteine variant (CV), and wild‐type Pru p 3 (WT) are purified from Escherichia coli. Variants display homogenous and stable protein conformations with an altered secondary structure in circular dichroism. PV shows enhanced long‐term storage capacities compared to CV similar to the highly stable WT. Using sera of 33 peach allergic patients, IgE‐binding activity is reduced by 97% (PV) and 71% (CV) compared to WT. Both molecules show strong hypoallergenicity in Pru p 3 ImmunoCAP cross‐inhibition and histamine release assays. Immunogenicity of PV is demonstrated with a phosphate‐based adjuvant formulation in a mouse model.Conclusions: An in silico approach is used to generate a PV without targeting disulfide bonds, T cell epitopes, or previously reported IgE epitopes of Pru p 3. PV is strongly hypoallergenic while structurally stable and immunogenic, thus representing a promising candidate for peach allergen immunotherapy.
- 17 October 2018
- Published by Taylor & Francis in Immunotherapy
- Vol. 10 (14) , 1253-1263
Tolerability and Positive Efficacy Results after Subcutaneous Immunotherapy with Parietaria Judaica Depot Extract
Aim: To evaluate tolerability and efficacy of Parietaria judaica subcutaneous immunotherapy on patients with allergic rhinoconjunctivitis. Patients & methods: 51 patients were assigned to build-up scheme (six increasing doses) of P. judaica depot native extract, plus three maintenance monthly administrations. Results: Out of 470 administered doses, only 3.8% elicited systemic reactions (1.5% nonspecific and 2.3% grade I). Concerning the exploratory efficacy parameters: cutaneous reactivity at the final visit versus baseline was significantly decreased; specific titers of IgG and IgG4 increased significantly and patients showed a significant decrease in the rhinitis symptoms score. Conclusion:P. judaica subcutaneous immunotherapy (Allergovac((R)) depot ROXALL Medicina Espana S.A., Zamudio, Spain) with an abbreviated up-dosing scheme showed an adequate safety and tolerability profile and induced preliminary efficacy changes.
- 17 October 2018
- Published by Taylor & Francis in Immunotherapy
- Vol. 10 (14) , 1253-1263
Tolerability and Positive Efficacy Results after Subcutaneous Immunotherapy with Parietaria Judaica Depot Extract
Aim: To evaluate tolerability and efficacy of Parietaria judaica subcutaneous immunotherapy on patients with allergic rhinoconjunctivitis. Patients & methods: 51 patients were assigned to build-up scheme (six increasing doses) of P. judaica depot native extract, plus three maintenance monthly administrations. Results: Out of 470 administered doses, only 3.8% elicited systemic reactions (1.5% nonspecific and 2.3% grade I). Concerning the exploratory efficacy parameters: cutaneous reactivity at the final visit versus baseline was significantly decreased; specific titers of IgG and IgG4 increased significantly and patients showed a significant decrease in the rhinitis symptoms score. Conclusion:P. judaica subcutaneous immunotherapy (Allergovac((R)) depot ROXALL Medicina Espana S.A., Zamudio, Spain) with an abbreviated up-dosing scheme showed an adequate safety and tolerability profile and induced preliminary efficacy changes.
- 1 January 2017
- Vol. 2017, 69-87
Validation of ELISA methods for quantification of the major birch allergen Bet v 1 (BSP090).
To date, the potency of allergen products in Europe is expressed in manufacturer-specific units relative to a product-specific in-house reference. Consequently, cross-product comparability of allergen products from different manufacturers with respect to strength and efficacy is impossible. The Biological Standardisation Programme (BSP) project BSP090 addresses this issue via the establishment of reference standards in conjunction with ELISA methods for the quantification of major allergens in allergen products. Since the initiation of BSP090, the recombinant major allergen Bet v 1 has been adopted by the European Pharmacopoeia Commission as a Chemical Reference Substance (CRS). In parallel, two sandwich ELISA systems for quantification of Bet v 1 were found suitable in preliminary phases of BSP090 to be validated in a large collaborative study. In this study, the candidate ELISA systems were compared with respect to accuracy, precision and variability. Thirteen participating laboratories tested model samples containing the CRS as well as spiked and unspiked birch pollen extracts. Both in pre-testing and in the collaborative study, the 2 candidate ELISA systems confirmed their suitability to quantify recombinant and native Bet v 1. As no clear-cut decision for one of the ELISA systems could be made based on the results of the collaborative study, a post-study testing was performed. Bet v 1 content of 30 birch pollen allergen products was determined in parallel in both ELISA systems. Consequently, 1 candidate ELISA system was selected to be proposed as the future European Pharmacopoeia standard method for Bet v 1 quantification.
- 1 January 2017
- Vol. 2017, 69-87
Validation of ELISA methods for quantification of the major birch allergen Bet v 1 (BSP090).
To date, the potency of allergen products in Europe is expressed in manufacturer-specific units relative to a product-specific in-house reference. Consequently, cross-product comparability of allergen products from different manufacturers with respect to strength and efficacy is impossible. The Biological Standardisation Programme (BSP) project BSP090 addresses this issue via the establishment of reference standards in conjunction with ELISA methods for the quantification of major allergens in allergen products. Since the initiation of BSP090, the recombinant major allergen Bet v 1 has been adopted by the European Pharmacopoeia Commission as a Chemical Reference Substance (CRS). In parallel, two sandwich ELISA systems for quantification of Bet v 1 were found suitable in preliminary phases of BSP090 to be validated in a large collaborative study. In this study, the candidate ELISA systems were compared with respect to accuracy, precision and variability. Thirteen participating laboratories tested model samples containing the CRS as well as spiked and unspiked birch pollen extracts. Both in pre-testing and in the collaborative study, the 2 candidate ELISA systems confirmed their suitability to quantify recombinant and native Bet v 1. As no clear-cut decision for one of the ELISA systems could be made based on the results of the collaborative study, a post-study testing was performed. Bet v 1 content of 30 birch pollen allergen products was determined in parallel in both ELISA systems. Consequently, 1 candidate ELISA system was selected to be proposed as the future European Pharmacopoeia standard method for Bet v 1 quantification.
Standardization of allergen products: 3. Validation of candidate European Pharmacopoeia standard methods for quantification of major birch allergen Bet v 1
Background: The BSP090 project aims at establishing European Pharmacopoeia Reference Substances in combination with the corresponding ELISA methods for the quantification of major allergens in allergen products. Two sandwich ELISAs proved suitable for quantification of Bet v 1, the major birch pollen allergen, in preceding phases of BSP090.Methods: Two Bet v 1‐specific ELISA systems were compared with respect to accuracy and precision in a ring trial including 13 laboratories. Model samples containing recombinant rBet v 1.0101 as well as native birch pollen extracts were measured independently at least three times in each facility. The assessment was completed with a comparative quantification of Bet v 1 in 30 marketed birch allergen products in one laboratory, simulating the future use as reference method.Results: In the collaborative study, both candidate ELISAs confirmed their suitability to quantify recombinant and native Bet v 1. ELISA‐A showed higher precision and lower interlaboratory variability, yet ELISA‐B exhibited slightly higher accuracy. Subsequent parallel measurement of Bet v 1 in a panel of ‘real‐life’ birch allergen products indicated better repeatability of ELISA‐B. Both systems detected substantial differences in Bet v 1 content between allergen products, but the effect was more pronounced using ELISA‐B due to persistently higher values compared to ELISA‐A.Conclusions: In the collaborative study, no deciding differences were observed between the two candidate ELISAs. Further comparison under conditions simulating the intended use combined with the criterion of long‐term availability enabled the selection of one Bet v 1‐specific ELISA for proposal as European Pharmacopoeia standard method.
Standardization of allergen products: 3. Validation of candidate European Pharmacopoeia standard methods for quantification of major birch allergen Bet v 1
Background: The BSP090 project aims at establishing European Pharmacopoeia Reference Substances in combination with the corresponding ELISA methods for the quantification of major allergens in allergen products. Two sandwich ELISAs proved suitable for quantification of Bet v 1, the major birch pollen allergen, in preceding phases of BSP090.Methods: Two Bet v 1‐specific ELISA systems were compared with respect to accuracy and precision in a ring trial including 13 laboratories. Model samples containing recombinant rBet v 1.0101 as well as native birch pollen extracts were measured independently at least three times in each facility. The assessment was completed with a comparative quantification of Bet v 1 in 30 marketed birch allergen products in one laboratory, simulating the future use as reference method.Results: In the collaborative study, both candidate ELISAs confirmed their suitability to quantify recombinant and native Bet v 1. ELISA‐A showed higher precision and lower interlaboratory variability, yet ELISA‐B exhibited slightly higher accuracy. Subsequent parallel measurement of Bet v 1 in a panel of ‘real‐life’ birch allergen products indicated better repeatability of ELISA‐B. Both systems detected substantial differences in Bet v 1 content between allergen products, but the effect was more pronounced using ELISA‐B due to persistently higher values compared to ELISA‐A.Conclusions: In the collaborative study, no deciding differences were observed between the two candidate ELISAs. Further comparison under conditions simulating the intended use combined with the criterion of long‐term availability enabled the selection of one Bet v 1‐specific ELISA for proposal as European Pharmacopoeia standard method.
- 12 January 2016
- Published by Taylor & Francis in Immunotherapy
- Vol. 8 (3) , 265-277
Randomized Dose–Response Study of Subcutaneous Immunotherapy with a Dermatophagoides pteronyssinus Extract in Patients with Respiratory Allergy
Aim: To evaluate the efficacy of Dermatophagoides pteronyssinus (DPT) subcutaneous immunotherapy in allergic rhinoconjunctivitis patients. Patients & methods: This 17-week double-blind study randomized 136 patients (95 evaluable) to five dose groups of DPT depot extract (0.0625–0.75 skin prick test [SPT] units) or placebo, administered in a six updosing schedule. Results: A dose–response was observed for clinical efficacy (allergen concentration needed to induce a positive nasal provocation test response from baseline to final visit) and safety (adverse reactions). Local and systemic reactions occurred with 14.8 and 6.4% of administered doses, respectively; a single anaphylactic reaction occurred in each of Groups 3, 4 and 5 (0.3% of doses). Conclusion: The risk–benefit profile appeared most favorable with a DPT dose of 0.125 SPT units.
- 12 January 2016
- Published by Taylor & Francis in Immunotherapy
- Vol. 8 (3) , 265-277
Randomized Dose–Response Study of Subcutaneous Immunotherapy with a Dermatophagoides pteronyssinus Extract in Patients with Respiratory Allergy
Aim: To evaluate the efficacy of Dermatophagoides pteronyssinus (DPT) subcutaneous immunotherapy in allergic rhinoconjunctivitis patients. Patients & methods: This 17-week double-blind study randomized 136 patients (95 evaluable) to five dose groups of DPT depot extract (0.0625–0.75 skin prick test [SPT] units) or placebo, administered in a six updosing schedule. Results: A dose–response was observed for clinical efficacy (allergen concentration needed to induce a positive nasal provocation test response from baseline to final visit) and safety (adverse reactions). Local and systemic reactions occurred with 14.8 and 6.4% of administered doses, respectively; a single anaphylactic reaction occurred in each of Groups 3, 4 and 5 (0.3% of doses). Conclusion: The risk–benefit profile appeared most favorable with a DPT dose of 0.125 SPT units.
- Open Access
- 28 February 2015
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 166 (1) , 41-51
Development of a Hypoallergenic Recombinant Parvalbumin for First-in-Man Subcutaneous Immunotherapy of Fish Allergy
Background: The FAST (food allergy-specific immunotherapy) project aims at developing safe and effective subcutaneous immunotherapy for fish allergy, using recombinant hypoallergenic carp parvalbumin, Cyp c 1. Objectives: Preclinical characterization and good manufacturing practice (GMP) production of mutant Cyp (mCyp) c 1. Methods:Escherichia coli-produced mCyp c 1 was purified using standard chromatographic techniques. Physicochemical properties were investigated by gel electrophoresis, size exclusion chromatography, circular dichroism spectroscopy, reverse-phase high-performance liquid chromatography and mass spectrometry. Allergenicity was assessed by ImmunoCAP inhibition and basophil histamine release assay, immunogenicity by immunization of laboratory animals and stimulation of patients' peripheral blood mononuclear cells (PBMCs). Reference molecules were purified wild-type Cyp c 1 (natural and/or recombinant). GMP-compliant alum-adsorbed mCyp c 1 was tested for acute toxicity in mice and rabbits and for repeated-dose toxicity in mice. Accelerated and real-time protocols were used to evaluate stability of mCyp c 1 as drug substance and drug product. Results: Purified mCyp c 1 behaves as a folded and stable molecule. Using sera of 26 double-blind placebo-controlled food-challenge-proven fish-allergic patients, reduction in allergenic activity ranged from 10- to 5,000-fold (1,000-fold on average), but with retained immunogenicity (immunization in mice/rabbits) and potency to stimulate human PBMCs. Toxicity studies revealed no toxic effects and real-time stability studies on the Al(OH)3-adsorbed drug product demonstrated at least 20 months of stability. Conclusion: The GMP drug product developed for treatment of fish allergy has the characteristics targeted for in FAST: i.e. hypoallergenicity with retained immunogenicity. These results have warranted first-in-man immunotherapy studies to evaluate the safety of this innovative vaccine.
- 28 February 2015
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 166 (1) , 41-51
Open AccessDevelopment of a Hypoallergenic Recombinant Parvalbumin for First-in-Man Subcutaneous Immunotherapy of Fish Allergy
Background: The FAST (food allergy-specific immunotherapy) project aims at developing safe and effective subcutaneous immunotherapy for fish allergy, using recombinant hypoallergenic carp parvalbumin, Cyp c 1. Objectives: Preclinical characterization and good manufacturing practice (GMP) production of mutant Cyp (mCyp) c 1. Methods:Escherichia coli-produced mCyp c 1 was purified using standard chromatographic techniques. Physicochemical properties were investigated by gel electrophoresis, size exclusion chromatography, circular dichroism spectroscopy, reverse-phase high-performance liquid chromatography and mass spectrometry. Allergenicity was assessed by ImmunoCAP inhibition and basophil histamine release assay, immunogenicity by immunization of laboratory animals and stimulation of patients' peripheral blood mononuclear cells (PBMCs). Reference molecules were purified wild-type Cyp c 1 (natural and/or recombinant). GMP-compliant alum-adsorbed mCyp c 1 was tested for acute toxicity in mice and rabbits and for repeated-dose toxicity in mice. Accelerated and real-time protocols were used to evaluate stability of mCyp c 1 as drug substance and drug product. Results: Purified mCyp c 1 behaves as a folded and stable molecule. Using sera of 26 double-blind placebo-controlled food-challenge-proven fish-allergic patients, reduction in allergenic activity ranged from 10- to 5,000-fold (1,000-fold on average), but with retained immunogenicity (immunization in mice/rabbits) and potency to stimulate human PBMCs. Toxicity studies revealed no toxic effects and real-time stability studies on the Al(OH)3-adsorbed drug product demonstrated at least 20 months of stability. Conclusion: The GMP drug product developed for treatment of fish allergy has the characteristics targeted for in FAST: i.e. hypoallergenicity with retained immunogenicity. These results have warranted first-in-man immunotherapy studies to evaluate the safety of this innovative vaccine.
- 6 February 2015
- Published by Taylor & Francis in Immunotherapy
- Vol. 7 (2) , 89-99
Phase I Study of Subcutaneous Allergen Immunotherapy With Dermatophagoides Pteronyssinus in Patients With Allergic Rhinoconjunctivitis With or Without Asthma
A double-blind placebo-controlled study was conducted according to EMA guidelines, to evaluate safety, tolerability and short-term treatment effects of three updosing regimens of Dermatophagoides pteronyssinus subcutaneous allergen immunotherapy. Forty-eight patients were randomized to groups: A (six weekly doses), B (eight weekly doses) or C (eight doses, two clustered doses over 3 weeks). The most frequent adverse events were local reactions. No serious adverse events were found. Severe systemic reactions were reported more frequently in Group C. Decreased cutaneous responses and increased specific IgGs were shown in all active groups, even within the short-term. Dermatophagoides pteronyssinus subcutaneous allergen immunotherapy in depot presentation exhibited good safety and tolerability. Group A seemed to show the best profile for further clinical development.
- 6 February 2015
- Published by Taylor & Francis in Immunotherapy
- Vol. 7 (2) , 89-99
Phase I Study of Subcutaneous Allergen Immunotherapy With Dermatophagoides Pteronyssinus in Patients With Allergic Rhinoconjunctivitis With or Without Asthma
A double-blind placebo-controlled study was conducted according to EMA guidelines, to evaluate safety, tolerability and short-term treatment effects of three updosing regimens of Dermatophagoides pteronyssinus subcutaneous allergen immunotherapy. Forty-eight patients were randomized to groups: A (six weekly doses), B (eight weekly doses) or C (eight doses, two clustered doses over 3 weeks). The most frequent adverse events were local reactions. No serious adverse events were found. Severe systemic reactions were reported more frequently in Group C. Decreased cutaneous responses and increased specific IgGs were shown in all active groups, even within the short-term. Dermatophagoides pteronyssinus subcutaneous allergen immunotherapy in depot presentation exhibited good safety and tolerability. Group A seemed to show the best profile for further clinical development.
- Open Access
- 10 June 2014
- Published by Institute of Rural Health in Annals of Agricultural and Environmental Medicine
- Vol. 21 (2) , 282-289
Molecular aerobiology – Plantago allergen Pla l 1 in the atmosphere
Exposure to airborne pollen from certain plants can cause allergic disease, but allergens can also be found in non-pollen-bearing fractions of ambient air. This may explain why the allergic response in susceptible patients does not always coincide with the presence and magnitude of airborne pollen counts. Plantago pollen is an important cause of pollinosis in northern Mediterranean countries, but it is difficult to determine its incidence in allergies because Plantago pollen appears in the atmosphere at the same time as grass pollen. The study aimed to investigate the relationship between the atmospheric concentration of Pla l 1 aeroallergen and Plantago pollen, and its incidence in a population group. Pollen was sampled using a Hirst-type volumetric trap (Burkard) and Burkard Cyclone sampler (Burkard) for Pla l 1 allergen. Allergen was determined with a Pla l 1-specific ELISA. Serum-specific IgE levels to several plant allergens were measured with the EAST system. The aerobiological dynamics of Plantago pollen grains and Pla l 1 did not follow the same trend, whereas the sum of Plantago with some other pollen types showed a more similar behaviour. Of the 118 subjects tested, sera from 52 contained IgE to Plantago pollen, but only 5 were monosensitized. The presence of Pla l 1 in the atmosphere depends not only on Plantago pollen but also on the pollen of other species from the Oleaceae family. Knowledge of the behaviour of allergen Pla l 1 in the atmosphere can help understand better asthma exacerbations associated with aeroallergens.
- 10 June 2014
- Published by Institute of Rural Health in Annals of Agricultural and Environmental Medicine
- Vol. 21 (2) , 282-289
Open AccessMolecular aerobiology – Plantago allergen Pla l 1 in the atmosphere
Exposure to airborne pollen from certain plants can cause allergic disease, but allergens can also be found in non-pollen-bearing fractions of ambient air. This may explain why the allergic response in susceptible patients does not always coincide with the presence and magnitude of airborne pollen counts. Plantago pollen is an important cause of pollinosis in northern Mediterranean countries, but it is difficult to determine its incidence in allergies because Plantago pollen appears in the atmosphere at the same time as grass pollen. The study aimed to investigate the relationship between the atmospheric concentration of Pla l 1 aeroallergen and Plantago pollen, and its incidence in a population group. Pollen was sampled using a Hirst-type volumetric trap (Burkard) and Burkard Cyclone sampler (Burkard) for Pla l 1 allergen. Allergen was determined with a Pla l 1-specific ELISA. Serum-specific IgE levels to several plant allergens were measured with the EAST system. The aerobiological dynamics of Plantago pollen grains and Pla l 1 did not follow the same trend, whereas the sum of Plantago with some other pollen types showed a more similar behaviour. Of the 118 subjects tested, sera from 52 contained IgE to Plantago pollen, but only 5 were monosensitized. The presence of Pla l 1 in the atmosphere depends not only on Plantago pollen but also on the pollen of other species from the Oleaceae family. Knowledge of the behaviour of allergen Pla l 1 in the atmosphere can help understand better asthma exacerbations associated with aeroallergens.
- 1 January 2014
- Vol. 24 (6) , 431-8
In vivo and in vitro testing with rAni s 1 can facilitate diagnosis of Anisakis simplex allergy.
Traditional diagnostic tests such as skin prick tests (SPT) and specific IgE (slgE) against whole Anisakis simplex extract have low specificity. Consequently, allergy to A simplex is overdiagnosed. Our aim was to compare tests used in component-resolved diagnosis. We evaluated 34 patients with allergy to A simplex, 15 patients with acute urticaria who were sensitized to A simplex but had no clinical history of allergy to A simplex, and 10 patients allergic to seafood. SPT, slgE (ELISA and ISAC-I 12), and the basophil activation test (BAT) were performed with A simplex whole extract and the molecular components rAni s 1, rAni s 3, and nPen m 1. Sensitivity and specificity were calculated and compared with different cutoffs. With the A simplex whole extract, SPT, slgE, and BAT yielded specificity values of 72%, 68%, and 70%, respectively, with a cutoff (wheal size) of 11.2 mm, an slgE value of 7.9 kUAIL, and a stimulation index of 1.9. Specificity increased to 100% using the molecular component rAni s 1 with SPT, slgE by ELISA, and ISAC-112. Neither rAni s 3 sensitization nor cross-reactivity with Pen m 1 was observed in patients sensitized to A simplex. rAni s 1 is recognized by 100% of our patients and is able to distinguish between patients allergic to A simplex and patients with acute urticaria who are sensitized to A simplex but have no clinical history of allergy to this parasite.
- 1 January 2014
- Vol. 24 (6) , 431-8
In vivo and in vitro testing with rAni s 1 can facilitate diagnosis of Anisakis simplex allergy.
Traditional diagnostic tests such as skin prick tests (SPT) and specific IgE (slgE) against whole Anisakis simplex extract have low specificity. Consequently, allergy to A simplex is overdiagnosed. Our aim was to compare tests used in component-resolved diagnosis. We evaluated 34 patients with allergy to A simplex, 15 patients with acute urticaria who were sensitized to A simplex but had no clinical history of allergy to A simplex, and 10 patients allergic to seafood. SPT, slgE (ELISA and ISAC-I 12), and the basophil activation test (BAT) were performed with A simplex whole extract and the molecular components rAni s 1, rAni s 3, and nPen m 1. Sensitivity and specificity were calculated and compared with different cutoffs. With the A simplex whole extract, SPT, slgE, and BAT yielded specificity values of 72%, 68%, and 70%, respectively, with a cutoff (wheal size) of 11.2 mm, an slgE value of 7.9 kUAIL, and a stimulation index of 1.9. Specificity increased to 100% using the molecular component rAni s 1 with SPT, slgE by ELISA, and ISAC-112. Neither rAni s 3 sensitization nor cross-reactivity with Pen m 1 was observed in patients sensitized to A simplex. rAni s 1 is recognized by 100% of our patients and is able to distinguish between patients allergic to A simplex and patients with acute urticaria who are sensitized to A simplex but have no clinical history of allergy to this parasite.